The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207272 · Cited by 224
RetractedFOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Castillo, C. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,480
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Regulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
Roles of HMGA proteins in cancer
Fusco, A., & Fedele, M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2271 · Cited by 716
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 519
Heinemann, V., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1988) · PubMed · Cited by 504
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M.-L., Fölsch, U. R., & Schäfer, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206390 · Cited by 474
Kummer, J. L., Rao, P. K., & Heidenreich, K. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20490 · Cited by 468
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J. D., Dumontet, C., Cass, C., Lai, R., & Mackey, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0224 · Cited by 430
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Ritchey, J., Stewart, A. K., Winchester, D. P., & Talamonti, M. S. (2007) · Cancer · doi:10.1002/cncr.22852 · Cited by 427
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann, V, Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09518-5 · Cited by 399
Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4203 · Cited by 351
HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
Eltzschig, H. K., Abdulla, P., Hoffman, E., Hamilton, K. E., Daniels, D., Schönfeld, C., Löffler, M., Reyes, G., Duszenko, M., Karhausen, J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050177 · Cited by 351
Lévi, F., Misset, J.-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J.-P., Kunstlinger, F., Lecouturier, S., Descorps-Declère, A., et al. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x · Cited by 343
Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi, M., Izawa, T., Mizukami, Y., Okumura, T., & Kohgo, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603559 · Cited by 328
Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1992) · PubMed · Cited by 328
Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., & Cass, C. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206952 · Cited by 318
The 5′-nucleotidases as regulators of nucleotide and drug metabolism
Hunsucker, S. A., Mitchell, B. S., & Spychala, J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.003 · Cited by 284
Davidson, J. D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L. M., & Slapak, C. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3363 · Cited by 280
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
Zhang, J., Visser, F., King, K. M., Baldwin, S. A., Young, J. D., & Cass, C. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9044-4 · Cited by 231
Singh, S., Srivastava, S. K., Bhardwaj, A., Owen, L. B., & Singh, A. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605968 · Cited by 225
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep, J. R., Loves, W. J. P., van der Wilt, C. L., Álvarez, E., Talianidis, I., Boven, E., Braakhuis, B. J. M., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (2002) · PubMed · Cited by 224
Ferreira, C. G., Span, S. W., Peters, G. J., Kruyt, F. A. E., & Giaccone, G. (2000) · PubMed · Cited by 223
Nakahira, S., Nakamori, S., Tsujie, M., Takahashi, Y., Okami, J., Yoshioka, S., Yamasaki, M., Marubashi, S., Takemasa, I., Miyamoto, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22390 · Cited by 209
Bouffard, D. Y., Laliberté, J., & Momparler, R. L. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90444-2 · Cited by 192
Nakashima, H., Nakamura, M., Yamaguchi, H., Yamanaka, N., Akiyoshi, T., Koga, K., Yamaguchi, K., Tsuneyoshi, M., Tanaka, M., & Katano, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4588 · Cited by 189
Morote–Garcia, J. C., Rosenberger, P., Nivillac, N. M. I., Coe, I. R., & Eltzschig, H. K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.037 · Cited by 187
Bergman, A. M., Eijk, P. P., Ruiz van Haperen, V. W. T., Smid, K., Veerman, G., Hubeek, I., van den IJssel, P., Ylstra, B., & Peters, G. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0989 · Cited by 182
van Haperen, V. W. T. R., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P. A., Hermsen, M. A. J. A., Vermorken, J. B., Pinedo, H. M., & Peters, G. J. (1994) · PubMed · Cited by 181
Costantino, C. L., Witkiewicz, A. K., Kuwano, Y., Cozzitorto, J. A., Kennedy, E. P., Dasgupta, A., Keen, J. C., Yeo, C. J., Gorospe, M., & Brody, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0371 · Cited by 181
Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression
Li, L., Fridley, B., Kalari, K., Jenkins, G., Batzler, A., Safgren, S., Hildebrandt, M., Ames, M., Schaid, D., & Wang, L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0405 · Cited by 177
Sun, H.-L., Liu, Y.-N., Huang, Y.-T., Pan, S.-L., Huang, D.-Y., Guh, J.-H., Lee, F.-Y., Kuo, S.-C., & Teng, C.-M. (2007) · Oncogene · doi:10.1038/sj.onc.1210169 · Cited by 171
An Undesired Effect of Chemotherapy
Arora, S., Bhardwaj, A., Singh, S., Srivastava, S. K., McClellan, S., Nirodi, C. S., Piazza, G. A., Grizzle, W. E., Owen, L. B., & Singh, A. P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.484576 · Cited by 166
Clinical pharmacology and pharmacogenetics of gemcitabine
Wong, A. L., Soo, R. A., Yong, W. P., & Innocenti, F. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902741828 · Cited by 163
Sebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
Skrypek, N., Duchêne, B., Hebbar, M., Leteurtre, E., SEUNINGEN, I. V., & Jonckheere, N. (2012) · Oncogene · doi:10.1038/onc.2012.179 · Cited by 157
Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy
Moniaux, N., Andrianifahanana, M., Brand, R. E., & Batra, S. K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602163 · Cited by 156
Ritzel, M. W. L., Ng, A. M. L., Yao, S. Y. M., Graham, K., Loewen, S. K., Smith, K. M., Hyde, R. J., Karpinski, E., Cass, C. E., Baldwin, S. A., et al. (2001) · Molecular Membrane Biology · doi:10.1080/09687680118530 · Cited by 141
Kasperczyk, H., Baumann, B., Debatin, K., & FuMa, S. (2008) · The FASEB Journal · doi:10.1096/fj.08-111096 · Cited by 140
Singh, A. P., Arora, S., Bhardwaj, A., Srivastava, S. K., Kadakia, M., Wang, B., Grizzle, W. E., Owen, L. B., & Singh, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409581 · Cited by 139
Pan, X., Arumugam, T., Yamamoto, T., Levin, P. A., Ramachandran, V., Ji, B., Lopez‐Berestein, G., Vivas‐Mejía, P. E., Sood, A. K., McConkey, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1539 · Cited by 129
Human Cytosolic 5′-Nucleotidase I
Hunsucker, S. A., Spychała, J., & Mitchell, B. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011218200 · Cited by 125
Ohhashi, S., Ohuchida, K., Mizumoto, K., Fujita, H., Egami, T., Yu, J., Toma, H., Sadatomi, S., Nagai, E., & Tanaka, M. (2008) · PubMed · Cited by 111
Hedgehog signaling pathway as a therapeutic target in various types of cancer
Onishi, H., & Katano, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02010.x · Cited by 110
Rompay, A. R. V., Johansson, M., & Karlsson, A. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.562 · Cited by 104
Morikawa, T., Maeda, D., Kume, H., Homma, Y., & Fukayama, M. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03725.x · Cited by 103
Huang, F., Zhuansun, Y., Zhuang, Y., WEI, S.-L., Tang, J., Chen, W., & Zhang, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1597 · Cited by 99
New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine
Veltkamp, S. A., Pluim, D., van Eijndhoven, M. A. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0137 · Cited by 98
Richards, N. G., Rittenhouse, D. W., Freydin, B., Cozzitorto, J. A., Grenda, D. R., Rui, H., Gonye, G., Kennedy, E. P., Yeo, C. J., Brody, J. R., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f1fd44 · Cited by 97
HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma
Liau, S., & Whang, E. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1450 · Cited by 88
Habiro, A., Tanno, S., Koizumi, K., Izawa, T., Nakano, Y., Osanai, M., Mizukami, Y., Okumura, T., & Kohgo, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.017 · Cited by 85
Xu, H., Faber, C., Uchiki, T., Racca, J. D., & Dealwis, C. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600440103 · Cited by 82
Kong, R., Sun, B., Jiang, H., Pan, S., Chen, H., Wang, S., Krissansen, G. W., & Sun, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.10.001 · Cited by 82
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity
Köpper, F., Bierwirth, C., Schön, M., Kunze, M., Elvers, I., Kranz, D., Saini, P., Menon, M., Walter, D., Sørensen, C. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304355110 · Cited by 82
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Gandhi, V. V., Legha, J., Chen, F., Hertel, L. W., & Plunkett, W. K. (1996) · PubMed · Cited by 76
van Haperen, V. W. T. R., Veerman, G., Vermorken, J. B., Pinedo, H. M., & Peters, G. J. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02402-6 · Cited by 75
Lau, J., Weatherdon, K. L., Skalski, V., & Hedley, D. W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602080 · Cited by 72
Walker, E. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2224 · Cited by 66
Nakashima, M., Adachi, S., Yasuda, I., Yamauchi, T., Kawaguchi, J., Itani, M., Yoshioka, T., Matsushima‐Nishiwaki, R., Hirose, Y., Kozawa, O., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.008 · Cited by 64
Ferrandina, G., Mey, V., Nannizzi, S., Ricciardi, S., Petrillo, M., Ferlini, C., Danesi, R., Scambia, G., & Tacca, M. D. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1073-y · Cited by 56
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine
Chandler, N. M., Canete, J. J., & Callery, M. P. (2004) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2004.09.054 · Cited by 56
Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells.
Kuramitsu, Y., Wang, Y., Taba, K., et al. (2012) · PubMed · Cited by 55
Applying next-generation sequencing to pancreatic cancer treatment
Mardis, E. R. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.126 · Cited by 45
Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination
Rudin, D., Li, L., Niu, N., Kalari, K. R., & Gilbert, J. A. (2011) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000107 · Cited by 44
Xu, M., Li, L., Liu, Z., Jiao, Z., Xu, P., Kong, X., Huang, H., & Zhang, Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.002 · Cited by 43
DNA Repair and Cancer Therapy: Targeting APE1/Ref-1 Using Dietary Agents
Raffoul, J. J., Heydari, A. R., & Hillman, G. G. (2012) · Journal of Oncology · doi:10.1155/2012/370481 · Cited by 43
Maasch, C., Vater, A., Buchner, K., Purschke, W. G., Eulberg, D., Vonhoff, S., & Klußmann, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178533 · Cited by 38
Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
Lili, L. N., Matyunina, L. V., Walker, L. D., Daneker, G. W., & McDonald, J. F. (2014) · Pancreas · doi:10.1097/mpa.0000000000000020 · Cited by 33
Cytosolic 5′-nucleotidase III (NT5C3): gene sequence variation and functional genomics
Aksoy, P., Zhu, M., Kalari, K. R., Moon, I., Pelleymounter, L. L., Eckloff, B. W., Wieben, E. D., Yee, V. C., Weinshilboum, R. M., & Wang, L. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832c14b8 · Cited by 33
Bahra, M., Kamphues, C., Boas‐Knoop, S., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e31822896dd · Cited by 32
Miyazaki, K. (1994) · Oncology Reports · doi:10.3892/or_00000004 · Cited by 31
Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer
Nagourney, R. A., Flam, M. S., Link, J. S., Hager, S. J., Blitzer, J. B., Lyons, W., Sommers, B. L., & Evans, S. S. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.052 · Cited by 27
Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma
Ogawa, M., Hori, H., Ohta, T., Onozato, K., Miyahara, M., & Komada, Y. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1781 · Cited by 26
Guo (2011) · Oncology Reports · doi:10.3892/or.2011.1139 · Cited by 23
Hodge, L. S., Taub, M. E., & Tracy, T. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040790 · Cited by 17
Xiong, G.-S., Sun, H., WU, S. M., & Jian Zhong, M. O. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00442.x · Cited by 16
Research works printed but not linked: 13
- Berger, 2013, Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma, Onkologie, 36, 763, 10.1159/000356811 · doi:10.1159/000356811
- Bergman, 2000, Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs, Eur. J. Cancer, 36, 1974, 10.1016/S0959-8049(00)00246-X · doi:10.1016/s0959-8049(00)00246-x
- Eda, 1998, The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase, Cancer Res., 58, 1165
- Hatzis, 1998, The intracellular localization of deoxycytidine kinase, J. Biol. Chem., 273, 30239, 10.1074/jbc.273.46.30239 · doi:10.1074/jbc.273.46.30239
- Hu, 2011, UMP/CMPK is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human RKO cells, PLoS One, 6, e19490, 10.1371/journal.pone.0019490 · DOI
- Kim, 2011, The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1, Mol. Cancer, 10, 98, 10.1186/1476-4598-10-98 · doi:10.1186/1476-4598-10-98
- Legarza, 2006, New molecular mechanisms of action of camptothecin-type drugs, Anticancer Res., 26, 3301
- Mazzon, 2003, Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy, Biochem. Pharmacol., 66, 471, 10.1016/S0006-2952(03)00290-9 · doi:10.1016/s0006-2952(03)00290-9
- Portal, 2014, Sustained response with gemcitabine plus nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy, Clin. Res. Hepatol. Gastroenterol., 38, e23, 10.1016/j.clinre.2014.01.005 · doi:10.1016/j.clinre.2014.01.005
- Ritzel, 2001, Mol. Membr. Biol., 18, 65, 10.1080/09687680010026313 · DOI
- Sarup, 1989, Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells, Biochem. Pharmacol., 38, 2601, 10.1016/0006-2952(89)90544-3 · doi:10.1016/0006-2952(89)90544-3
- Watanabe, 2012, HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines, Cancer Lett., 315, 18, 10.1016/j.canlet.2011.10.005 · doi:10.1016/j.canlet.2011.10.005
- Xu, 1992, Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine, Biochem. Pharmacol., 44, 1819, 10.1016/0006-2952(92)90077-V · doi:10.1016/0006-2952(92)90077-v
Cited by
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 548
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 540
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Metadata
- Authors
- de Sousa Cavalcante, L., & Monteiro, G.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 741
- Pages
- 8-16
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2045246542
- Cited by
- 576
- References
- 93
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2009/01303-1, 2011/04938-8)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.